Peer-influenced content. Sources you trust. No registration required. This is HCN.
Journal of Clinical Oncology
Gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) AML but seldom reduces FLT3mut burden or induces sustained efficacy. This phase Ib open-label, dose-escalation/dose-expansion study enrolled 61 patients (63% having received prior FLT3 therapy) to receive 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The combination of venetoclax and gilteritinib was associated with high mCRc and FLT3 molecular response rates regardless of prior FLT3 inhibitor exposure, but did require dose interruptions for myelosuppression.
Hematology/Oncology August 8th 2022
Even after allogeneic hematopoietic stem-cell transplant (HCT), poor outcomes are typically the case in patients with TP53-mutant (mTP53) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The data from recent trials using the combination of eprenetapopt (APR-246) and azacitidine showed positive preclinical results in mTP53 AML/MDS, and this trial sought to assess the efficacy and safety of the eprenetapopt and azacitidine combination as maintenance therapy after allogeneic HCT in patients with mTP53 AML or MDS.
Hematology/Oncology July 18th 2022
Blood Advances
The study confirmed the high unmet need among older adults with AML, namely that overall survival (OS) without transplant is poor and consistent with other studies. The authors also remark that a “definitive evidence-based recommendation favoring venetoclax and azacitidine (ven/aza) or CPX-351 in older adults will require a randomized trial.”
Blood
Major advances in the understanding of acute myeloid leukemia (AML) has prompted the need for this update, which includes a revised European LeukemiaNet (ELN) genetic risk classification, revised response criteria, and treatment recommendations from the 2010 and 2017 editions.
The International Consensus Classification (ICC) of myeloid neoplasms and acute leukemia was developed as a result of the recent advances in doctors’ understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials.
Hematology/Oncology July 11th 2022
Medical Professionals Reference (MPR)
Copiktra (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), is indicated for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least 2 prior therapies. Based on the results of a clinical trial evaluating the long-term effects of the drug, the FDA recommends that health care providers evaluate the risks and benefits of continuing Copiktra vs. prescribing an alternative therapy.
Hematology/Oncology July 5th 2022